Sep 16, 2020 / 06:00PM GMT
David Reed Risinger - Morgan Stanley, Research Division - MD in Equity Research and United States Pharmaceuticals Analyst
Great. Good afternoon, everyone, and thanks for joining our session with Supernus. I need to -- my name is Dave Risinger, and I cover both U.S. and major specialty pharmaceuticals at Morgan Stanley. I do need to read a disclaimer. Please note that this webcast is for Morgan Stanley's clients and appropriate Morgan Stanley employees only. It's not for members of the press. If you're a member of the press, please disconnect and reach out separately. For important disclosures, please see www.morganstanley.com/researchdisclosures. And if you have any questions, please feel free to reach out to your Morgan Stanley sales representative.
So it's very much my pleasure to welcome Jack Khattar. He's the company's founder and CEO; and also, Greg Patrick, the company's CFO, may be joining as well later. But I'm sure Jack can handle any and all questions. So we're pleased to have him with us.
Supernus Pharmaceuticals Inc at Morgan Stanley Global Healthcare Conference (Virtual) Transcript
Feb 09, 2024
Already have an account? Log in
Get the full story
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent 
4.6 out of 5 
Trustpilot
Trustpilot
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers